Modeling Tumor Dynamics and Overall Survival in Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib

被引:12
|
作者
Suleiman, Ahmed Abbas [1 ]
Frechen, Sebastian [1 ]
Scheffler, Matthias [2 ]
Zander, Thomas [2 ]
Kahraman, Deniz [3 ]
Kobe, Carsten [3 ]
Wolf, JRgen [2 ]
Nogova, Lucia [2 ]
Fuhr, Uwe [1 ]
机构
[1] Univ Hosp Cologne, Dept Pharmacol, Clin Pharmacol Unit, D-50931 Cologne, Germany
[2] Univ Hosp Cologne, Ctr Integrated Oncol Cologne, Dept Internal Med 1, Lung Canc Grp Cologne, D-50931 Cologne, Germany
[3] Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, Dept Nucl Med, D-50931 Cologne, Germany
关键词
Modeling; NSCLC; PET; Survival; Erlotinib; POSITRON-EMISSION-TOMOGRAPHY; PHASE-II; SIZE; PET; OPPORTUNITIES; PREDICTION; ONCOLOGY; EVALUATE; DESIGN; RECIST;
D O I
10.1097/JTO.0000000000000330
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Pharmacostatistical models can quantify different relationships and improve decision making in personalized medicine and drug development. Our objectives were to develop models describing non-small-cell lung cancer (NSCLC) dynamics during first-line treatment with erlotinib, and survival of the cohort. Methods: Data from patients with advanced NSCLC (n = 39) treated first-line with erlotinib (150 mg/day) were analyzed using nonlinear mixed effects modeling. Exposure-driven disease-drug models were built to describe tumor metabolic and proliferative dynamics evaluated by positron emission tomography (PET) using 2'-deoxy-2'-[F-18] fluoro-D-glucose (FDG) and 3'-[F-18] fluoro-3'-deoxy-L-thymidine (FLT), respectively, at baseline, weeks 1 and 6 after starting erlotinib treatment. A parametric time-to-event model was built to describe overall survival (OS). Demographics, histology, mutational, smoking, and baseline performance statuses were tested for their effects on models developed, in addition to tumor dynamics on survival. Results: An exponential relationship described progression, and a concentration-driven drug effect model described erlotinib effect. An activating epidermal growth factor receptor (EGFR) mutation increased the drug effect as assessed using FDG-PET by 2.19-fold (95% confidence interval [CI]: 1.35-4.44). An exponential distribution described the times-to-death distribution. Baseline FDG uptake (p=0.0005; hazard ratio [HR] = 1.26 for every unit increase, 95% CI: 1.13-1.42) and relative change in FDG uptake after 1 week of treatment (p=0.0073; HR=0.84 for every 10% drop, 95% CI: 0.71-0.91) were significant OS predictors irrespective of the EGFR mutational status. FLT-PET was statistically less significant than FDG-PET for OS prediction. Conclusion: Models describing tumor dynamics and survival of advanced NSCLC patients first-treated with erlotinib were developed. The impacts of different covariates were quantified.
引用
收藏
页码:84 / 92
页数:9
相关论文
共 50 条
  • [21] Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival
    Mizuki Nishino
    Xinan Wang
    Biagio Ricciuti
    Shu-Chi Tseng
    Hyesun Park
    Joao V. Alessi
    Victor R. Vaz
    Hiroto Hatabu
    Xihong Lin
    David C. Christiani
    Mark M. Awad
    [J]. European Radiology, 2023, 33 : 7284 - 7293
  • [22] Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib
    Xiaoqin Li
    Shan Liu
    Hangang Gu
    Deqiang Wang
    [J]. Journal of Cancer Research and Clinical Oncology, 2012, 138 : 1963 - 1969
  • [23] Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival
    Nishino, Mizuki
    Wang, Xinan
    Ricciuti, Biagio
    Tseng, Shu-Chi
    Park, Hyesun
    Alessi, Joao V.
    Vaz, Victor R.
    Hatabu, Hiroto
    Lin, Xihong
    Christiani, David C.
    Awad, Mark M.
    [J]. EUROPEAN RADIOLOGY, 2023, 33 (10) : 7284 - 7293
  • [24] Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib
    Li, Xiaoqin
    Liu, Shan
    Gu, Hangang
    Wang, Deqiang
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (11) : 1963 - 1969
  • [25] Evaluating the Impact of Bevacizumab Maintenance Therapy on Overall Survival in Advanced Non-Small-Cell Lung Cancer
    Dranitsaris, George
    Beegle, Nancy
    Ravelo, Arliene
    Kalberer, Traci
    Yu, Elaine
    Thomas, Sachdev
    [J]. CLINICAL LUNG CANCER, 2013, 14 (02) : 120 - 127
  • [26] Impact of prophylactic Cranial Irradiation on Overall Survival of Patients with advanced non-small-cell Lung Cancer
    Schmidt, Julia
    Appold, Steffen
    Troost, Esther G. C.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 (05) : 453 - 455
  • [27] Time trends in overall survival (OS) gain in advanced non-small-cell lung cancer (NSCLC).
    Saad, Everardo D.
    Buyse, Marc E.
    Jassem, Jacek
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer
    Cheema, P. K.
    Burkes, R. L.
    [J]. CURRENT ONCOLOGY, 2013, 20 (02) : E150 - E160
  • [29] Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib
    Yin, Anyue
    Veerman, G. D. Marijn
    van Hasselt, Johan G. C.
    Steendam, Christi M. J.
    Dubbink, Hendrikus Jan
    Guchelaar, Henk-Jan
    Friberg, Lena E.
    Dingemans, Anne-Marie C.
    Mathijssen, Ron H. J.
    Moes, Dirk Jan A. R.
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (04): : 612 - 623
  • [30] A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients
    Suleiman, Ahmed Abbas
    Frechen, Sebastian
    Scheffler, Matthias
    Zander, Thomas
    Nogova, Lucia
    Kocher, Martin
    Jaehde, Ulrich
    Wolf, Juergen
    Fuhr, Uwe
    [J]. AAPS JOURNAL, 2015, 17 (06): : 1483 - 1491